Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment, a ...

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

Changes in A1c and body weight were evaluated. TAKEAWAY: Tirzepatide was associated with a 42% lower risk for all-cause mortality than GLP-1 RAs (adjusted hazard ratio, 0.58; 95% CI, 0.45-0.75).

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

The researchers found that their hypothesis was correct. In patients treated with tirzepatide, LV mass decreased by 11 g (0.4 oz), and cardiac adipose tissue dropped by 45 mL (1.5 fl oz).